Autoplaque vs Eko Analysis Software
AI Verdict
Choose Autoplaque if…
Choose Autoplaque if your primary need is a detailed, quantitative analysis of coronary arteries and atherosclerotic plaque from CT angiography images. This tool is ideal for radiologists and cardiologists requiring precise measurements of luminal stenoses and plaque characteristics to inform advanced risk stratification and treatment planning based on imaging data.
View Autoplaque →Choose Eko Analysis Software if…
Choose Eko Analysis Software if you require an accessible, AI-powered tool for the early detection and ongoing monitoring of cardiovascular diseases like heart murmurs and atrial fibrillation through auscultation. This software is best suited for clinicians in primary care, emergency medicine, or remote monitoring scenarios who need to quickly screen and track cardiac rhythm and valvular health using a digital stethoscope.
View Eko Analysis Software →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Autoplaque | Eko Analysis Software |
|---|---|---|
| Deployment | Workstation-based post-processing application, runs on Windows or Mac OS. | Unknown |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Eko Analysis SoftwareEko Analysis Software integrates with a mobile app and digital stethoscope, offering a highly accessible and intuitive point-of-care experience for a broader range of clinicians. Autoplaque, being workstation-based and focused on complex imaging analysis, likely requires a more specialized user and a steeper learning curve.
Clinical Value
AutoplaqueAutoplaque provides FDA-cleared quantitative analysis of coronary plaques and luminal stenoses from CT angiography images, offering deep, objective insights crucial for managing complex cardiovascular disease and guiding treatment strategies. While Eko offers valuable early detection, Autoplaque's detailed plaque characterization represents a more advanced and impactful clinical contribution.
Pricing & Value
Eko Analysis SoftwareEko Analysis Software employs a transparent freemium pricing model, allowing users to access basic features for free and clearly understand the cost of advanced functionalities. Autoplaque's pricing is not disclosed, making it impossible to evaluate its value proposition or compare costs effectively.
Enterprise Readiness
Eko Analysis SoftwareEko Analysis Software explicitly states HIPAA compliance and offers a Business Associate Agreement (BAA), which are fundamental requirements for enterprise adoption in healthcare. Its cloud-based deployment also offers superior scalability and easier management compared to Autoplaque's workstation-based solution, which lacks explicit compliance statements in the provided data.
Innovation
AutoplaqueAutoplaque's application of AI for highly sophisticated quantitative analysis of coronary plaque morphology and luminal stenoses from CT angiography images represents a more specialized and technically challenging innovation. This offers deeper diagnostic insights that are difficult to achieve manually, pushing the boundaries of cardiac imaging diagnostics.
Support & Docs
Eko Analysis SoftwareEko Devices, as a commercial entity, provides clear and accessible support resources on its website, including FAQs, user manuals, and direct customer service contact. Information regarding comprehensive support and documentation for Autoplaque, developed by a medical center, is not readily available or detailed in the provided information.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Autoplaque | Eko Analysis Software |
|---|---|---|
| Name | Autoplaque | Eko Analysis Software |
| Company | Cedars-Sinai Medical Center: AIM | Eko Devices |
| Description | Autoplaque, developed by Cedars-Sinai AIM, is an FDA-cleared AI-powered software for quantitative analysis of coronary plaques and luminal stenoses from CT angiography images, aiding in heart attack risk prediction and treatment guidance. | Eko Analysis Software is an FDA-cleared AI-powered tool that integrates with Eko's digital stethoscopes and mobile app to assist clinicians in the early detection of cardiovascular diseases like heart murmurs and atrial fibrillation. |
| Key Features | AI-powered quantitative analysis of atherosclerotic plaque; Detection and characterization of coronary artery plaque; Measurement of luminal stenoses; Analysis of coronary anatomy and pathology from CT Angiographic images; Workstation-based post-processing application; Automated vessel, plaque, and lumen segmentation (reviewable and editable by clinician); Review of heart and coronary vessels in Multiplanar Reformatting (MPR), curved MPR, and straightened MPR views; Measurement of vessel diameter and area | FDA-cleared AI for heart murmur detection; FDA-cleared AI for atrial fibrillation (AFib) detection; Detection of normal sinus rhythm; Calculation of cardiac time intervals (heart rate, QRS duration); Wireless auscultation with Bluetooth-enabled devices; Recording, playback, and annotation of heart sounds and ECGs; Visualization of phonocardiograms (PCG) and ECG tracings; Secure cloud-based storage of recordings within the US |
Videos
Demos, reviews, and walkthroughs featuring Autoplaque and Eko Analysis Software.